Monthly Archives: May 2006

The Dangers of a Recess Appointment for Dr. von Eschenbach

Posted on May 31, 2006 by Mark Senak

Related to yesterday’s posting, because of the unorthodox way in which Plan B was handled, Acting Commissioner Andrew C. von Eschenbach faces the prospect of not ever being confirmed (though he actually had nothing to do with the issue).  There … Continue reading →

Posted in FDA Image | Comments Off on The Dangers of a Recess Appointment for Dr. von Eschenbach

Good Time to Move on Plan B

Posted on May 30, 2006 by Mark Senak

Last week, former Acting Commissioner and former Commissioner Lester B. Crawford admitted in a deposition that he acted to pre-empt FDA staff from approving the OTC switch of Plan B, according to a report in the Baltimore Sun.  What he … Continue reading →

Posted in FDA Policy, OTC Switches | Comments Off on Good Time to Move on Plan B

Memorial Day

Posted on May 29, 2006 by Mark Senak

With an eye towards remembering those who have demonstrated the courage of their convictions, have a safe and pleasant Memorial Day.

Posted in Uncategorized | Comments Off on Memorial Day

Weekly Roundup – 5-26-06

Posted on May 26, 2006 by Mark Senak

After a two-week hiatus, Weekly Roundup is back.  Bad Legislative Action – An amendment to a House appropriations bill that would have provided for greater FDA authority over drug safety in post-marketing studies was stripped from the legislation.  Expect hearings … Continue reading →

Posted in Weekly Roundup | Comments Off on Weekly Roundup – 5-26-06

Vitamins, Canada and a Lesson for NIH

Posted on May 25, 2006 by Mark Senak

With proposals before Congress (see Legislative section to the right) to allow the FDA additional power to regulate the industry of vitamins and supplements, there have been recent developments of note. Last week, the National Institutes of Health held a … Continue reading →

Posted in DSHEA, Vitamins and Supplements | Comments Off on Vitamins, Canada and a Lesson for NIH